Welcome to our dedicated page for Novanta SEC filings (Ticker: NOVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Novanta Inc. (Nasdaq: NOVT) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a global supplier of core technology solutions for medical, life science, and advanced industrial OEMs. This SEC filings page brings together those disclosures so investors can review the company’s regulatory record in one place.
Among the most frequently referenced filings are current reports on Form 8-K, where Novanta announces quarterly financial results, provides non-GAAP metrics such as Adjusted EBITDA and Adjusted Diluted EPS, and discloses material events. Recent 8-K filings have covered results for specific fiscal quarters, revisions to financial guidance, changes in Board composition, and details of share repurchase authorizations.
Filings also document capital markets and financing transactions, including the underwriting agreement and terms of Novanta’s tangible equity units offering, which combines prepaid stock purchase contracts with senior amortizing notes due 2028. Related 8-Ks describe settlement mechanics, interest and installment payments, and the listing of the units under the symbol NOVTU. Other filings outline the terms of the company’s senior credit facilities under its Fourth Amended and Restated Credit Agreement and subsequent amendments, including leverage and coverage covenants.
Through this page, users can access Novanta’s 10-K annual reports and 10-Q quarterly reports (when filed), as well as Forms 4 and other ownership-related filings, via real-time updates from EDGAR. AI-powered summaries help explain complex sections, highlight key changes from prior periods, and clarify the implications of items such as guidance revisions, credit agreement provisions, and share repurchase programs.
Whether reviewing earnings-related disclosures, tracking capital structure developments, or examining governance and compensation information, this filings hub provides a structured entry point into Novanta’s SEC reporting history.
The holder of NOVT common stock has filed a Rule 144 notice to sell 43,920 shares. The planned sale is to be executed through J.P. Morgan Securities LLC on Nasdaq, with an approximate sale date of 01/21/2026. The filing shows these shares were acquired through a mix of stock option exercise on 01/21/2026 and multiple compensation awards from the issuer between 2021 and 2024. The number of shares of the same class outstanding is listed as 35,775,123; this is a baseline figure, not the amount being sold.
Novanta, Inc. insider plans a new stock sale under Rule 144. Matthijs Glastra filed a notice to sell up to 7,500 shares of Novanta common stock through Merrill Private Wealth Management on NASDAQ, with an aggregate market value of $1,050,000. The filing notes that 35,775,123 Novanta shares were outstanding at the time of the notice, which is a baseline figure, not the amount being sold.
The shares to be sold were acquired as equity compensation via restricted stock units on January 2, 2024 (418 shares), February 20, 2024 (1,474 shares), and February 26, 2024 (5,608 shares), all from Novanta, Inc. In the past three months, the filer has already sold 323 Novanta common shares for gross proceeds of $41,990 and 6,177 shares for $803,010. The approximate date for the new sale is listed as January 21, 2026.
Novanta Inc. reported an equity award to its General Counsel, Alexander Manganiello. On January 15, 2026, he received 10,513 Restricted Stock Units (RSUs), each representing the right to receive one Novanta common share upon vesting. The RSUs were granted at a stated price of $0 per unit, reflecting that this is a compensation award rather than an open‑market purchase.
The RSUs vest in three equal installments on January 15, 2027, January 15, 2028, and January 15, 2029. Following this grant, Manganiello is shown as beneficially owning 10,513 derivative securities directly, all tied to Novanta common stock through these RSUs.
Novanta Inc. Chief Executive Officer and director Matthijs Glastra reported an insider sale of common stock. On January 9, 2026, a total of 6,177 shares of Novanta common stock were sold at $130 per share, coded as an open market sale.
The filing notes that these sales were carried out under a pre-established Rule 10b5-1 trading plan that was adopted on September 11, 2025 through a trust for which the reporting person’s spouse is a trustee. After this transaction, Glastra beneficially owned 78,867 shares directly and 54,382 shares indirectly through the Matthijs Glastra 2021 Irrevocable Trust, indicating he continues to hold a significant equity position in Novanta.
Novanta Inc. Chief Executive Officer and director Matthijs Glastra reported a small insider sale of company stock. On January 8, 2026, he sold 323 shares of Novanta Inc. common stock at a weighted-average price of $130.14 per share, coded as an open market sale. The transaction was carried out under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025, which is designed to allow automated trading according to preset instructions.
Following this sale, Glastra beneficially owns 85,044 shares directly and an additional 54,382 shares indirectly through the Matthijs Glastra 2021 Irrevocable Trust, for which his spouse serves as trustee.
A holder of Novanta, Inc. common stock filed a notice to sell 6,177 shares through Merrill Private Wealth Management on the NASDAQ market. The filing reports an aggregate market value of 803,010 for these shares, compared with 35,775,123 common shares outstanding. The seller acquired the 6,177 shares as restricted stock units from Novanta on 01/02/2024 as equity compensation. The notice also discloses that the same person sold 323 common shares for gross proceeds of 41,990 on 01/08/2026.
A holder has filed a notice of proposed sale under Rule 144 for 323 shares of Novanta, Inc. common stock. The shares are planned to be sold on or about 01/08/2026 on the NASDAQ market through Merrill Private Wealth Management. The filing notes that 35,775,123 shares of Novanta common stock were outstanding. These 323 shares were originally acquired on 01/02/2024 as restricted stock units from Novanta, Inc. as a form of equity compensation, with payment also dated 01/02/2024 and described as equity compensation.
Novanta Inc. director Wilson Frank Anders reported equity award activity on January 2, 2026. He settled 1,325 Restricted Stock Units (RSUs), which were each the economic equivalent of one Novanta common share, into 1,325 shares of common stock, bringing his directly held common stock to 3,947 shares following the transaction.
On the same date, he received a new grant of 1,799 RSUs, each representing the right to receive one Novanta common share on the first anniversary of the grant date (or the next business day). These RSUs were fully vested and non‑forfeitable on the grant date, leaving him with 1,799 RSUs beneficially owned after the reported transactions.
Novanta Inc. director Mauricio Maxine Lum reported equity compensation activity involving restricted stock units (RSUs) and common shares. On January 2, 2026, 1,325 RSUs, each equal to one Novanta common share, were settled into 1,325 shares of common stock at a reported price of $0 per share, bringing Lum’s directly held common stock to 4,548 shares.
On the same date, Lum received a new award of 1,799 RSUs. Each of these RSUs represents the right to receive one Novanta common share on the first anniversary of the grant date (or the next business day). The filing notes that these RSUs were fully vested and non-forfeitable on the grant date and that Lum now directly holds 1,799 RSUs after the reported transactions.
Novanta Inc. director Darlene J. S. Solomon reported restricted stock unit activity and related common share ownership changes. On January 2, 2026, 1,325 restricted stock units were settled into 1,325 Novanta common shares at a price of $0 per share, leaving her with 3,541 common shares held directly. The filing also reports a grant of 1,799 restricted stock units on the same date, each representing the right to receive one Novanta common share on the first anniversary of the grant date. These newly granted units were fully vested and non-forfeitable on the grant date, and she holds 1,799 restricted stock units directly after the transactions.